Market Signal

Plum, Celcuity, and VITL Secure Funding and Revenue Prospects in Healthcare

Sourced from 3 publications

  • •Plum (Indian health benefits platform) raised ₹193 crore in Series B funding after becoming profitable.
  • •Celcuity (US biotech firm) estimates a $2.5 billion peak annual revenue for its drug, gedatolisib.
  • •VITL (startup) secured $7.5 million to enhance its e-prescribing marketplace targeting cash-pay clinics.

Sources

Plum bags ₹193 cr from Peak XV in Series B funding after turning profitable

Business-standard

Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivot...

Seekingalpha

Riding the GLP-1 boom, VITL lands $7.5M to overhaul cash-pay clinic prescribing

TechCrunch

Was this story useful?

Curated from 3 sources. Every summary is reviewed for accuracy, but may still contain errors. We always link to original sources for verification.

Related Stories

IFM Investors Warns AI and Energy Spending Will Fuel Decades of Inflation

2026-03-26

6.4

Borr Drilling Holds M&A Call as KB Home, Glass House Report Quarterly Results

2026-03-25

3.2

Oil Prices Drop Up to 6% as Trump Signals Openness to Iran Negotiations

2026-03-25

6.8

About Meridian

Meridian is a free daily newsletter delivering signal-scored news stories with forward-looking analysis every morning. Stories are scored across six criteria (global leverage, capital impact, temporal durability, career relevance, decision utility, and narrative clarity) then assigned to Big Signal, Core, or Quick tiers.

Get Meridian in your inbox

The stories that matter, every morning at 06:00.